体外研究 (In Vitro) |
IHMT-TRK-284 (Compound 34) (0-10 µM, 72 h) shows antiproliferative effects against BaF3 cells, a panel of kinase transformed BaF3 cells, and KM-12-LUC cells.
IHMT-TRK-284 (0-10 µM, 24 h) induces apoptosis and arrests the cell cycle into G0/G1 phase in KM-12-LUC cells.
IHMT-TRK-284 exerts its inhibitory effect to the colon cancer cells through on-target inhibition of TRK.
IHMT-TRK-284 could overcome drug resistant mutants including V573M and F589L in the ATP binding pocket as well as G667C/S in the DFG region.
IHMT-TRK-284 shows selectivity over VEGFR2 kinase.
Cell Proliferation Assay
| Cell Line: |
BaF3 cells, a panel of kinase transformed BaF3 cells, and KM-12-LUC cells |
| Concentration: |
0-10 µM |
| Incubation Time: |
72 h |
| Result: |
Showed antiproliferative effects against BaF3 cells, a panel of kinase transformed BaF3 cells, and KM-12-LUC cells. GI50 for KM-12-LUC cells was 0.002 µM.
Antiproliferative effects of IHMT-TRK-284 against a panel of kinase transformed BaF3 cells.
| Target |
BaF3-TEL-ABL |
BaF3-TEL-CSF1R |
BaF3-TEL-KIT |
BaF3-TEL-PDGFRα |
BaF3-TEL-PDGFRβ |
BaF3-TEL-TRKA |
BaF3-TEL-TRKB |
BaF3-TEL-TRKC |
| GI50 (nM) |
411.1 |
4 |
923.2 |
1.7 |
1.4 |
8.5 |
8.2 |
27.3 |
Antiproliferative effects of IHMT-TRK-284 against a panel of TRKs wt/mutants transformed BaF3 cells (n = 3).
Showed antiproliferative effects with GI50s of 1.4 ± 0.011, 0.007 ± 0.001, 0.003 ± 0.001, 0.004 ± 0.001, 0.194 ± 0.013, 0.034 ± 0.002, 0.002 ± 0.001 μM against BaF3, BaF3-LMNA-TRKA, BaF3-LMNA-TRKA-V573M, BaF3-LMNA-TRKA-F589L, BaF3-LMNA-TRKA-G595R, BaF3-LMNA-TRKA-G667C, BaF3-LMNA-TRKA-G667S cells, respectively.
|
Western Blot Analysis
| Cell Line: |
BaF3-TEL-TRKA, BaF3-TEL-TRKB, BaF3-TEL-TRKC, BaF3-LMNATRKA-V573M, BaF3-LMNA-TRKA-F589L, BaF3-LMNA-TRKA-G595R, BaF3-LMNA-TRKA-G667C/S, and KM-12-LUC cells |
| Concentration: |
0, 0.01, 0,03, 0.1, 0.3, 1, 3, and 10 µM |
| Incubation Time: |
2 h |
| Result: |
In transformed BaF3 cells: Inhibited the phosphorylation of TRKA Y490 (EC50 = 0.026 µM) and corresponding tyrosine residues TRKB Y515 (EC50 = 0.069 µM) and TRKC Y516 (EC50 = 0.029 µM); potently inhibited the phosphorylation of Y490 in V573M, F589L, and G667C/S mutants with EC50s of 0.013 µM, 0.021 µM, 0.067 µM, and 0.074 µM respectively. In KM-12-LUC cells: Blocked the phosphorylation of TRKA Y490 at the concentration of 0.01 µM; remarkably inhibited the phosphorylation of downstream signaling mediators AKT T308/S473 and ERK1/2 (T202/Y204) (EC50 less than 0.03 µM).
|
Apoptosis Analysis
| Cell Line: |
KM-12-LUC cells |
| Concentration: |
0, 0.01, 0,03, 0.1, 0.3, 1, 3, and 10 µM |
| Incubation Time: |
24 h |
| Result: |
Induced dose-dependent cell apoptotic death.
|
Cell Cycle Analysis
| Cell Line: |
KM-12-LUC cells |
| Concentration: |
0, 0.01, 0,03, 0.1, 0.3, 1, 3, and 10 µM |
| Incubation Time: |
24 h |
| Result: |
Arrested the cell cycle into G0/G1 phase.
|
|
体内研究 (In Vivo) |
IHMT-TRK-284 (Compound 34) (40 and 80 mg/kg; p.o.; daily, 10 days) shows good in vivo PK and antitumor efficacy properties.
| Animal Model: |
Four-week old female nu/nu mice, one million BaF3-TELTRKA, BaF3-TEL-TRKB, BaF3-TEL-TRKC, BaF3-LMNA-TRKA-F589L, BaF3-LMNA-TRKA-G667S, and five million KM-12-LUC cells in DMEM medium were formulated as a 1:1 mixture with matrigel and injected into the subcutaneous space on the right flank of nu/nu mice |
| Dosage: |
40 mg/kg and 80 mg/kg |
| Administration: |
Daily oral gavage, 10 days |
| Result: |
Dose-dependently inhibited the BaF3-TEL-TRKA, BaF3-TEL-TRKB, and BaF3-TEL-TRKC tumor progression with TGI (tumor growth inhibition) of 68%, 93%, and 58%. Dose-dependently inhibited the tumor progression and exhibited the TGI of 93% at 40 mg/kg/day and 95% at 80 mg/kg/day in KM-12-LUC cells inoculated xenograft mouse model. Potently inhibited the tumor growth with TGI values of 88% and 89% respectively at 80 mg/kg dosage in BaF3- LMNA-TRKA-F589L and BaF3-LMNA-TRKA-G667S cells. |
| Animal Model: |
Mice, sprague dawley rats, and beagle dogs |
| Dosage: |
1 mg/kg and 10 mg/kg |
| Administration: |
Intravenous injection and oral administration (Pharmacokinetic Analysis)
|
| Result: |
Pharmacokinetic study of IHMT-TRK-284 in mice, sprague dawley rats, and beagle dogsa
| Parameter |
Mice i.v. (1 mg/kg) |
Mice p.o. (10 mg/kg) |
Rats i.v. (1 mg/kg) |
Rats p.o. (10 mg/kg) |
Beagle Dogs i.v. (1 mg/kg) |
Beagle Dogs p.o. (10 mg/kg) |
AUC(0-t) (ng/mL*h) |
748 |
1431 |
393 |
952 |
323 |
464 |
| Tmax (h) |
0.033 |
1.5 |
0.03 |
4.7 |
0.08 |
4.3 |
| T1/2 (h) |
2.6 |
3.4 |
2.7 |
2.5 |
0.03 |
11.8 |
| Vz (mL/kg) |
4934 |
31567 |
9682 |
|
| 分子量 |
|
| Formula |
|
| CAS 号 |
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
| 纯度 & 产品资料 |
Data Sheet (541 KB)
产品使用指南 (1538 KB)
|
| 参考文献 |
|
IHMT-TRK-284 相关分类
-
Cancer
-
肿瘤靶向治疗
肿瘤耐药
肿瘤代谢与转移
-
Neuronal Signaling
Protein Tyrosine Kinase/RTK
Apoptosis
-
Trk Receptor
c-Fms
PDGFR
Bcr-Abl
c-Kit
Apoptosis
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
动物实验计算换算器
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
-
客服
2851296953
18923798467
微信洽谈
| |